Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year?HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year?Zacks Equity ResearchZacksJanuary 3, 2020ReblogShareTweetShareThe Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Chimerix (CMRX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Chimerix is a member of the Medical sector. This group includes 909 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CMRX is currently sporting a Zacks Rank of #2 (Buy).Within the past quarter, the Zacks Consensus Estimate for CMRX's full-year earnings has moved 13.18% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.According to our latest data, CMRX has moved about 2.96% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 0.12% on average. As we can see, Chimerix is performing better than its sector in the calendar year.Breaking things down more, CMRX is a member of the Medical - Products industry, which includes 86 individual companies and currently sits at #102 in the Zacks Industry Rank. On average, this group has gained an average of 0.42% so far this year, meaning that CMRX is performing better in terms of year-to-date returns.Going forward, investors interested in Medical stocks should continue to pay close attention to CMRX as it looks to continue its solid performance.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chimerix, Inc. (CMRX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHere are 5 reasons the stock market is having its worst decline since 2008, and only one of them is the coronavirusMarketWatchMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoOil’s Worst Week Since 2014 Puts Pressure on OPEC+ to RespondBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceMarket Recap: Friday, Dec. 13Yahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance